Sunandana Chandra, MD, MS

Sunandana Chandra, MD, MS, closes by sharing advice for patients with metastatic uveal melanoma.

An overview of the treatment options for patients with mUM who ineligible for treatment with tebentafusp.

Dr Sunandana Chandra highlights her personal experience in prescribing tebentafusp and other therapies for mUM, and discusses the educational resources and advocacy organizations that she encourages patients to look into to help make an informed decision about their treatment regimens.

An oncologist outlines which patients with mUM are eligible for bispecific T-cell receptor immunotherapy, discusses logistical and safety considerations, and explains why pre-treatment HLA testing is required for those considering the regimen.

Sunandana Chandra, MD, MS, discusses safety and efficacy data from the IMCgp100-202 trial on tebentafusp, and comments on the clinical implications of these data.

An expert provides an overview of the historical and currently available treatment options in metastatic uveal melanoma (mUM), including the bispecific T-cell receptor immunotherapy tebentafusp (“teh-BEN-tah-fuhsp”).

Dr Sunandana Chandra describes the typical symptoms that patients with uveal melanoma experience, the prevalent asymptomatic patient population, and how optometrists and ophthalmologists may be involved in the diagnostic process.

Sunandana Chandra, MD, MS, explains how uveal melanoma is different from cutaneous melanoma, including prevalence, molecular mutations, and survival prognosis after metastasis.